» Articles » PMID: 33033509

The Characteristics and Long-term Survival of Patients with Colorectal Liver Metastases with Pathological Complete Response After Chemotherapy

Overview
Journal J Cancer
Specialty Oncology
Date 2020 Oct 9
PMID 33033509
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Preoperative chemotherapy is widely used for colorectal liver metastasis (CRLM). Pathological complete response (PCR) after chemotherapy indicates complete tumor regression and an extremely favorable prognosis. This study aimed to explore the characteristics and long-term survival of CRLM patients with pCR, who underwent surgery after preoperative chemotherapy. We retrospectively analyzed the clinical data of 494 CRLM patients who underwent hepatectomy after preoperative chemotherapy between January 2006 and January 2019. pCR was defined as the absence of any cancer cells on pathological examination. Thirty (6.07%) patients achieved pCR after preoperative chemotherapy; 70% patients who achieved pCR did not experience recurrence and were cured after hepatectomy. The long-term prognosis of patients with pCR was extremely favorable, with 10-year overall and disease-free survivals of 85.2% and 73.7%, respectively; these were significantly better than those of patients without pCR (31.3% and 15.2%, respectively). Liver metastases <3 cm, preoperative carcinoembryonic antigen level ≤20 ng/mL, primary T stage 1-2, and right-sided primary tumors were independent predictors for pCR. pCR occurred in 6% of patients with CRLM after preoperative chemotherapy. Patients with a smaller tumor burden are more likely to benefit from chemotherapy and achieve pCR.

Citing Articles

Pre-hepatectomy dynamic circulating tumor DNA to predict pathologic response to preoperative chemotherapy and post-hepatectomy recurrence in patients with colorectal liver metastases.

Liu M, Bao Q, Zhao T, Huang L, Zhang D, Wang Y Hepatol Int. 2024; 18(3):1029-1039.

PMID: 38427145 DOI: 10.1007/s12072-023-10628-4.


Neoadjuvant chemotherapy weakens the prognostic value of the pathological tumor burden score for colorectal cancer liver metastases.

Liao L, Sun H, He J, Liu Y, Pan Z, Wu X BMC Surg. 2023; 23(1):271.

PMID: 37689651 PMC: 10492270. DOI: 10.1186/s12893-023-02145-w.


Combined Hepatic Arterial Infusion Pump and Systemic Chemotherapy in the Modern Era for Chemotherapy-Naive Patients with Unresectable Colorectal Liver Metastases.

Verheij F, Kuhlmann K, Silliman D, Soares K, Kingham T, Balachandran V Ann Surg Oncol. 2023; 30(13):7950-7959.

PMID: 37639032 DOI: 10.1245/s10434-023-14073-3.


Disappearing Colorectal Liver Metastases: Do We Really Need a Ghostbuster?.

Anselmo A, Cascone C, Siragusa L, Sensi B, Materazzo M, Riccetti C Healthcare (Basel). 2022; 10(10).

PMID: 36292345 PMC: 9602313. DOI: 10.3390/healthcare10101898.


The Pathologic Complete Response Ratio of Liver Metastases Represents a Valuable Prognostic Indicator.

Xu Y, He J, Li W, Zhang W, Liu S, He J Pathol Oncol Res. 2022; 28:1610663.

PMID: 36147656 PMC: 9485473. DOI: 10.3389/pore.2022.1610663.


References
1.
Matsumoto T, Hasegawa S, Hida K, Kawada K, Sakai Y, Sugihara K . Role of Repeat Resection in Patients With Metastatic Colorectal Cancer: A Multicenter Retrospective Study. Dis Colon Rectum. 2019; 62(5):561-567. DOI: 10.1097/DCR.0000000000001311. View

2.
Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

3.
Nordlinger B, Sorbye H, Glimelius B, Poston G, Schlag P, Rougier P . Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2013; 14(12):1208-15. DOI: 10.1016/S1470-2045(13)70447-9. View

4.
Gruenberger T, Arnold D, Rubbia-Brandt L . Pathologic response to bevacizumab-containing chemotherapy in patients with colorectal liver metastases and its correlation with survival. Surg Oncol. 2012; 21(4):309-15. DOI: 10.1016/j.suronc.2012.07.003. View

5.
Dy G, Krook J, Green E, Sargent D, Delaunoit T, Morton R . Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: results from Intergroup N9741. J Clin Oncol. 2007; 25(23):3469-74. DOI: 10.1200/JCO.2007.10.7128. View